Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and efficacy study of cenobamate in pediatric subjects with focal seizures
2020-005344-27Phase 3Active
- Sponsor
- SK Life Science, Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in Focal onset seizure and epilepsy, sponsored by SK Life Science, Inc. Primary endpoint: Treatment-emergent adverse events and serious adverse events during first year. Started Jul 2021; status: active.
02
Drugs
cenobamate
03
Conditions
Focal onset seizureepilepsy
Beyond the preview
Go deeper on 2020-005344-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005344-27.